Cellevate demonstrerar uppskalning av sina Cellevat3d-nanofiber-mikrobärare

Cellevate med bas i Lund har visat att deras banbrytande Cellevat3d nanofiber mikrobärarteknologi som skapar en sann tredimensionell cellodlingsmiljö kan skalas upp. Detta kan ge tre gånger så mycket viralt vektorutbyte jämfört med befintliga lösningar, snabbare processer och effektivare uppskalning. Tekniken kommer att lanseras på BIO-Europe nästa vecka.

Cellevate, an innovative biotech company developing next-generation cell culture systems to revolutionize biomanufacturing, is excited to announce the successful scale-up of its ground-breaking Cellevat3d^® nanofiber microcarriers funded by Vinnova/STUNS Life Science. The study was performed at Testa Center in Uppsala, Sweden, in the 10-liter Xcellerex XDR-10 single-use stirred tank bioreactor (Cytiva).

The nanofiber-based Cellevat3d microcarriers represent a potential paradigm shift in bioprocessing. They have up to 60x the surface area of “traditional” carriers, creating a true three-dimensional cell culture environment, significantly increasing viable cell densities and viral vector yields in stirred tank reactors. Cellevate plans to launch Cellevat3d nanofiber microcarriers in November 2024.

“Scaling up at Testa Center in 10 L stirred tank bioreactor with our new category of nanofiber-based cell culture systems, while maintaining all the cell culture parameters unchanged from lab scale, is a great achievement. The study also demonstrated the ease of use and ease of implementation in bioreactors and our ability to meet industrial bioprocessing scale up demand. We have now added the last piece of the puzzle in securing the success of the global commercial launch of the world’s first nanofiber-based cell culture systems designed to boost viral vector productivity, in just a few weeks in November 2024 at BIO-Europe in Stockholm,” says Laura Chirica, CEO of Cellevate.

“We’re thrilled to have supported Cellevate in their recent 3-week project at Testa Center, where they utilized our XDR10 bioreactor to scale up mammalian adherent cells. It’s fantastic to see innovative biotech companies like Cellevate leveraging our facilities to push the boundaries of cell culture technology. We’re proud to play a part in fostering advancements that help accelerate novel biotherapies development and production”, says Jesper Hedberg, CEO, Testa Center.